REPL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
REPL is not a clear good buy right now for a beginner long-term investor, even with $50,000-$100,000 to deploy. The stock has meaningful upside potential if the FDA path succeeds, but the setup is still event-driven and volatile rather than a clean long-term entry. Because the user is impatient and does not want to wait for a better entry, I would still not call this a buy today; I would rate it a hold until the FDA catalyst is resolved.
Current price is 11.26 versus previous close 11.58, so the stock is slightly weaker at the latest close, though it has recently been supported by positive regulatory news. Trend structure is mixed: SMA_5 > SMA_20 > SMA_200 is bullish, but MACD histogram is -0.0448 and negatively expanding, which suggests short-term momentum is fading. RSI_6 at 71.273 indicates the stock is stretched near overbought levels rather than offering an attractive low-risk entry. Key levels are Pivot 11.19, resistance at 12.19 and 12.81, and support at 10.19 and 9.57. Overall, the chart shows an uptrend that is losing momentum and is vulnerable to pullback after the recent rally.
The biggest positive catalyst is FDA acceptance of the resubmitted BLA for RP1 plus nivolumab, with an August 2, 2026 action date and an expected AdCom in late July. Analyst sentiment has improved sharply after the resubmission acceptance, and some firms now describe the path to approval as meaningfully de-risked. If approval arrives, the shares could re-rate higher and remove financing overhang concerns.
The stock remains heavily dependent on a single regulatory outcome, so the thesis is binary. The news flow still reflects prior FDA setbacks, including prior complete response letters and a volatile approval process. Technical momentum is not fully confirming the bullish story, and the historical pattern data suggests a negative short-term drift. The company also continues to show substantial losses, which keeps long-term fundamental risk elevated if approval does not materialize.
The latest financial information points to continued operating losses rather than strong fundamental earnings power. Replimune reported a full-year loss of $313.94 million, worse than the prior year's $247.30 million loss, and FY GAAP EPS of -$3.38 missed expectations by $0.02. That means the latest reported season was the fiscal fourth quarter and full year 2026 results mentioned by analysts, and the company is still in a cash-consuming development stage. Growth is being driven by regulatory progress rather than current profitability.
Analyst sentiment has improved materially over the last month. Wedbush raised its target to $9 and stayed Neutral, JPMorgan upgraded to Overweight with a $17 target, and BMO double-upgraded to Outperform with a $16 target, all after FDA acceptance of the resubmitted application. Earlier in April, Wedbush and Leerink were negative after the second CRL, so the Wall Street view has shifted from skeptical to more constructive. The pros argue the FDA path is de-risked and approval could unlock upside and ease financing pressure, while the cons remain the prior regulatory failures, the binary catalyst dependence, and the lack of underlying profitability. There is no recent politician or influential insider buying or selling data, and no congress trading activity in the last 90 days.
